Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case

The drug dasatinib is a new therapeutic option for patients with chronic myeloid leukemia (CML) as well as acute lymphocytic lymphoblastic leukemia (ALL). However, the scientific literature has not reached a consensus regarding the types of secondary ophthalmologic effects that this drug may have. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Monge, Katia Sotelo, Gálvez-Ruiz, Alberto, Alvárez-Carrón, Alberto, Quijada, César, Matheu, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487962/
https://www.ncbi.nlm.nih.gov/pubmed/26155085
http://dx.doi.org/10.1016/j.sjopt.2014.12.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487962/
https://www.ncbi.nlm.nih.gov/pubmed/26155085
http://dx.doi.org/10.1016/j.sjopt.2014.12.004

Ejemplares similares